Lupin gets USFDA nod for generic Antifungal drug

The product will be manufactured at Lupin’s facility in Pithampur, India.

48
USFDA
Picture: Pixabay

Last Updated on July 16, 2021 by The Health Master

Global pharma major Lupin Limited announced the US launch of tavaborole topical solution, 5% having received an approval from the United States Food and Drug Administration (USFDA).

The product will be manufactured at Lupin’s facility in Pithampur, India.

Tavaborole topical solution, 5%, is generic equivalent of Kerydin topical solution, 5%, of Anacor Pharmaceuticals, Inc. and is an oxaborole antifungal indicated for the topical treatment of onychomycosis of the toenails due to trichophyton rubrum or trichophyton mentagrophytes.

Tavaborole topical solution, 5% has an estimated annual sales of US$ 53 million in the US, according to IQVIA MAT May 2021.

Unichem gets tentative USFDA nod for drug to treat Diabetes

Alembic gets USFDA final nod for Erlotinib Tablets

Alembic gets USFDA nod for drug for the treatment of Depression

USFDA approves Abbott’s Stent to treat high bleeding risk patients

Zydus Cadila gets USFDA nod for drug to treat HIV infection

Alembic gets USFDA nod for Nitrofurantoin Capsules USP

Govt waives import duty on these Raw Materials and APIs

NPPA seeks details for 29 formulations from Drug Mfrs to fix…

Serum Institute to start Mfg Sputnik vaccine in September

Nutraceutical Industry: A trending Market

6 reasons: How Gel creams are different from traditional cold creams

FDA seizes fake drugs worth Rs. 50 lakh from drug dealers

Telegram
WhatsApp
Facebook
LinkedIn
Google-news

Enter your email address:

Delivered by FeedBurner